Hormone Therapy

Exploring the availability and acceptability of hormone replacement therapy in LMICs using insights of pharmacists (MARIE Sri Lanka WP2a).

TL;DR

Significant disparities exist in HRT access, availability and affordability across LMICs, with urban-rural gaps further compounding inequities, underscoring the urgent need for inclusive, equitable strategies in menopausal care and women's health policy in resource-limited settings.

Key Findings

68.9% of pharmacists reported that HRTs were available for dispensing in their respective countries, with wide variation across the six LMICs surveyed.

  • Nepal reported the highest proportion of HRT availability at 92.7%.
  • Nigeria reported the lowest proportion of HRT availability at 42%.
  • Other countries surveyed included Malaysia, Sri Lanka, Tanzania, and Ghana.
  • The survey was conducted from January 1 to March 31, 2025, with 331 total pharmacist respondents.

HRT costs varied widely across the six LMICs, with Sri Lanka reporting the highest prices and Malaysia the lowest.

  • The study assessed HRT pricing as part of the questionnaire covering availability, pricing, and perceived barriers to use.
  • Cost was identified as one of the key barriers to HRT access under the category of economic constraints.
  • Wide cost variation across countries highlights affordability as a major equity concern in LMICs.

Key barriers to HRT use identified by pharmacists included low health literacy, economic constraints, and limited healthcare access.

  • These barriers were identified through an anonymous online questionnaire completed by pharmacists across six LMICs.
  • Urban-rural gaps were noted as further compounding inequities in HRT access and availability.
  • 57.4% of respondents were based in urban areas, suggesting potential underrepresentation of rural perspectives.

A total of 331 pharmacists across six LMICs participated in the cross-sectional survey, with relatively balanced distribution across countries and sexes.

  • Country distribution: Ghana (18.4%), Sri Lanka (17.5%), Tanzania (16.9%), Nepal (16.6%), Malaysia (15.4%), and Nigeria (15.1%).
  • Respondents were almost equally distributed between sexes, with 50.8% female.
  • Most respondents were aged 26–35 years (49.0%).
  • The majority worked in private community pharmacies (41.7%) or government hospitals (32.6%).
  • 57.4% were based in urban areas.

HRT remains underutilised and under-researched in low- and middle-income countries despite its potential to alleviate menopausal symptoms.

  • The study was conducted as part of the Global Menopause Project (MARIE Sri Lanka WP2a).
  • Pharmacists working in community, hospital, and private sector settings were recruited across Malaysia, Sri Lanka, Nepal, Nigeria, Ghana, and Tanzania.
  • The questionnaire was piloted prior to dissemination and assessed HRT availability, pricing, and perceived barriers to use.

Have a question about this study?

Citation

Pathiraja V, Kurmi O, Toh T, Eleje G, Tweneboah-Koduah F, Mbwele B, et al.. (2025). Exploring the availability and acceptability of hormone replacement therapy in LMICs using insights of pharmacists (MARIE Sri Lanka WP2a).. Scientific reports. https://doi.org/10.1038/s41598-025-18083-x